{
  "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "docSlug": "2296286e07283457e97b21dc9ce59469",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 46,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": "Layout splits into three quadrants of charts (survival %, tumor response %, median survival days) plus a navy summary band; Immix Biopharma logo top-right and page number 26 bottom-right.",
  "elementsJson": null,
  "metadataConfidence": 0.86,
  "imagePath": null,
  "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/26",
  "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "deckJsonHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0.json",
  "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.13,
        "w": 0.33,
        "x": 0.66,
        "y": 0.8
      },
      "kind": "callout",
      "text": "IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "581ece0e-f873-49a7-9367-f2d05aabb371",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.18,
        "x": 0.66,
        "y": 0.17
      },
      "kind": "chart",
      "text": "Median Survival In Genetic (KPC) Pancreatic Cancer Mouse Model — IMX-110 + anti-PD-1: 63 days (+50%) vs 4-drug combination (gemcitabine, nab-paclitaxel, 2 immunotherapies (anti-PD-1, anti-CD40)): 42 days",
      "attrs": {
        "x_axis": [
          "IMX-110 + anti-PD-1",
          "4-drug combination"
        ],
        "uplift_pct": 50,
        "y_values_days": [
          63,
          42
        ]
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32d0eeb0-145a-4ebf-9171-b9b24840f8b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.32,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Best % Change from Baseline in Size of Tumor — Standard of Care (doxorubicin) Entire Group: +23%; IMX-110 Treatment Responder Mean: -41%; IMX-110 Treatment Entire Group Mean: -32%",
      "attrs": {
        "x_axis": [
          "Standard of Care Entire Group",
          "IMX-110 Responder Mean",
          "IMX-110 Entire Group Mean"
        ],
        "y_values_pct": [
          23,
          -41,
          -32
        ]
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7300396-8768-4bf2-b30c-2f1f89c238da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.22,
        "x": 0.06,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Percent Survival After One Cycle of Treatment At Day 22 — IMX-110: 75% vs Trabectedin (YONDELIS, Janssen / J&J): 0%",
      "attrs": {
        "x_axis": [
          "IMX-110",
          "Trabectedin"
        ],
        "y_label": "Percent Survival",
        "y_values_pct": [
          75,
          0
        ]
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcc85709-5592-4a05-b27e-26c911b70607",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.16,
        "x": 0.82,
        "y": 0.02
      },
      "kind": "image",
      "text": "IMMIX BIOPHARMA",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5c11690-8b37-420d-8b27-a0a93c031f8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.3,
        "y": 0.13
      },
      "kind": "list",
      "text": "In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs • One cycle of IMX-110 produced 75% survival vs. 0% for Trabectedin • May 20, 2022 Press Release",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22318fd0-e0b1-467d-8ee6-b09d2ba7273a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.3,
        "x": 0.36,
        "y": 0.46
      },
      "kind": "list",
      "text": "IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line therapy-resistant cancer – soft tissue sarcoma (STS) mice study • IMX-110 response rate surpassed standard of care doxorubicin's response rate of 0% after 1 cycle of treatment in the same study • January 12, 2022 Press Release",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "648417f4-0fb3-49e8-9d6e-5e0dcaefc2db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.15,
        "x": 0.84,
        "y": 0.17
      },
      "kind": "list",
      "text": "IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system • Historically, 42-days is the median survival produced by a 4-drug combination of 2 chemotherapies and 2 immunotherapies in the same genetic pancreatic cancer mouse model according to Winograd et al., 2015 • 2022 plan to commence combination IMX-110 + BeiGene anti-PD-1 tislelizumab Phase 1b/2a clinical trial in advanced solid tumors • January 25, 2022 Press Release",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6768e2dd-307c-4258-ac65-877a5d1d6259",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.18,
        "x": 0.66,
        "y": 0.49
      },
      "kind": "source-note",
      "text": "Source: Immix Biopharma, Inc., Adapted from Winograd, et al., 2015",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3784db47-1fe0-4870-816a-af61e257933e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.66,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "January 25, 2022 10:15 ET | Source: Immix Biopharma, Inc.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cf2281c-4fe8-4f45-b3f7-d407a0e84c25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.78,
        "x": 0.01,
        "y": 0.02
      },
      "kind": "title",
      "text": "IMX-110 Preclinical Data Provides Translational Rationale & PD-1 Combination Rationale",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92a6e617-2f2b-4124-934a-a7a1777cbabd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.04,
        "y": 0.4
      },
      "kind": "title",
      "text": "IMX-110 Demonstrated Response Rate Better than Standard of Care",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00449e95-fb70-40cc-ab79-17cf9fce7550",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.08,
        "y": 0.11
      },
      "kind": "title",
      "text": "IMX-110 Demonstrated Improved Survival",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70b4aed0-c43d-44f5-a4b3-52f589f9798e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.32,
        "x": 0.66,
        "y": 0.1
      },
      "kind": "title",
      "text": "IMX-110 +anti-PD-1 Potential Survival Benefit Better than Comparable Median Survival",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfa78709-024d-484d-a0a1-a562ba788bca",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "Action Titles",
      "slug": null,
      "matchId": "81acf9a8-05ae-4366-a3ed-6a2484616a6d",
      "evidence": "Section headers and the navy summary band state the takeaway, not just the topic.",
      "confidence": 0.75
    },
    {
      "name": "Peer gap chart",
      "slug": null,
      "matchId": "a7ef079e-649e-4b5d-8ee2-e93d7a5d46c9",
      "evidence": "Bar charts contrast IMX-110 against Trabectedin standard-of-care and a 4-drug combination benchmark.",
      "confidence": 0.7
    },
    {
      "name": "Quantification",
      "slug": null,
      "matchId": "6ecee323-a866-4906-99bb-b62bfcd3631c",
      "evidence": "Headline numbers (75% vs 0%, -41% vs +23%, 63 vs 42 days) anchor each claim.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}